Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 3 Biotech
1 Abdom Radiol (NY)
1 Asia Pac J Clin Oncol
1 Biochem Biophys Res Commun
1 Biochim Biophys Acta Mol Basis Dis
3 BJU Int
1 BMC Cancer
1 BMC Med
2 BMC Urol
1 Bull Cancer
1 Cancer Res Treat
1 Cancer Sci
1 Clin Cancer Res
1 Comput Math Methods Med
3 Curr Opin Urol
1 Eur Urol Focus
1 Evid Based Complement Alternat Med
1 Folia Med (Plovdiv)
1 Free Radic Biol Med
2 Front Genet
2 Front Immunol
1 Front Oncol
1 Hinyokika Kiyo
1 Int Braz J Urol
1 Int J Surg
4 Int J Urol
1 J Biomol Tech
1 J Environ Public Health
1 J Exp Clin Cancer Res
1 J Glob Antimicrob Resist
1 J Hematol Oncol
1 J Med Case Rep
1 J Transl Med
2 J Urol
1 Minerva Surg
1 Minerva Urol Nephrol
1 Mol Imaging Biol
1 Mol Ther Oncolytics
1 Pathobiology
1 Pathology
1 PLoS One
1 Sci Rep
4 Urol Oncol
5 Urology
4 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    3 Biotech

  1. WARE AP, Kabekkodu SP, Chawla A, Paul B, et al
    Diagnostic and prognostic potential clustered miRNAs in bladder cancer.
    3 Biotech. 2022;12:173.
    PubMed         Abstract available

    Abdom Radiol (NY)

  2. BALASUBRAMANYA R, Shanbhogue AK, Ramani NS, Morani AC, et al
    Mesenchymal neoplasms of the urinary bladder: a comprehensive review with focus on cross-sectional imaging findings.
    Abdom Radiol (NY). 2022;47:2881-2895.
    PubMed         Abstract available

    Asia Pac J Clin Oncol

  3. HWANG I, Park I, Yoon SK, Lee JL, et al
    Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.
    Asia Pac J Clin Oncol. 2022;18:371-377.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  4. TANG F, Yu H, Wang X, Shi J, et al
    NCAPG promotes tumorigenesis of bladder cancer through NF-kappaB signaling pathway.
    Biochem Biophys Res Commun. 2022;622:101-107.
    PubMed         Abstract available

    Biochim Biophys Acta Mol Basis Dis

  5. TENG H, Li Q, Gou M, Liu G, et al
    Lamprey immunity protein enables early detection and recurrence monitoring for bladder cancer through recognizing Neu5Gc-modified uromodulin glycoprotein in urine.
    Biochim Biophys Acta Mol Basis Dis. 2022;1868:166493.
    PubMed         Abstract available

    BJU Int

  6. KOBAYASHI M, Narita S, Matsui Y, Kanda S, et al
    Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
    BJU Int. 2022;130:226-234.
    PubMed         Abstract available

  7. AHMADI H, Reddy S, Nguyen C, Douglawi A, et al
    Long-term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder.
    BJU Int. 2022;130:200-207.
    PubMed         Abstract available

  8. WALRAVEN JEW, Ripping TM, Oddens JR, van Rhijn BWG, et al
    The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.
    BJU Int. 2022 Jul 21. doi: 10.1111/bju.15856.
    PubMed         Abstract available

    BMC Cancer

  9. MIYAI K, Kawamura K, Ito K, Matsukuma S, et al
    Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
    BMC Cancer. 2022;22:787.
    PubMed         Abstract available

    BMC Med

  10. LI J, Liang Y, Fan J, Xu C, et al
    DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.
    BMC Med. 2022;20:222.
    PubMed         Abstract available

    BMC Urol

  11. PALACKA P, Janega P, Polakova H, Slopovsky J, et al
    Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab.
    BMC Urol. 2022;22:108.
    PubMed         Abstract available

  12. WU Q, Cai L, Yuan B, Cao Q, et al
    The application value of multi-parameter cystoscope in improving the accuracy of preoperative bladder cancer grading.
    BMC Urol. 2022;22:111.
    PubMed         Abstract available

    Bull Cancer

  13. MATTE P, Campedel L
    [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
    Bull Cancer. 2022;109.

    Cancer Res Treat

  14. KIM R, Hong JY, Lee J, Kwon GY, et al
    Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Cancer Res Treat. 2022;54:894-906.
    PubMed         Abstract available

    Cancer Sci

  15. IWAMURA H, Mizuno K, Akamatsu S, Hatakeyama S, et al
    Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.
    Cancer Sci. 2022;113:2434-2445.
    PubMed         Abstract available

    Clin Cancer Res

  16. PIETZAK EJ, Whiting K, Srinivasan P, Bandlamudi C, et al
    Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2022 Jul 14. pii: 707011. doi: 10.1158/1078-0432.CCR-22-1006.
    PubMed         Abstract available

    Comput Math Methods Med

  17. LUO H, Xu C, Ge B, Wang T, et al
    CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.
    Comput Math Methods Med. 2022;2022:8100325.
    PubMed         Abstract available

    Curr Opin Urol

  18. SORIA F, Dutto D, Gontero P
    Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022 Jul 15. pii: 00042307-990000000-00019.
    PubMed         Abstract available

  19. SCHOBER JP, Plimack E, Geynisman D, Zibelman M, et al
    The past, present, and future of pT0 in bladder cancer clinical trials.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00026.
    PubMed         Abstract available

  20. LONATI C, Simeone C, Suardi N, Briganti A, et al
    Micropapillary bladder cancer: an evolving biology.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00030.
    PubMed         Abstract available

    Eur Urol Focus

  21. AHMED ME, Todenhofer T, Karnes RJ, Seiler R, et al
    Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.
    Eur Urol Focus. 2022 Jul 14. pii: S2405-4569(22)00138.
    PubMed         Abstract available

    Evid Based Complement Alternat Med

  22. CHEN J, Gu Z, Pan Y, Zhang Y, et al
    Effect of Radical Laparoscopic Surgery and Conventional Open Surgery on Surgical Outcomes, Complications, and Prognosis in Elderly Patients with Bladder Cancer.
    Evid Based Complement Alternat Med. 2022;2022:1681038.
    PubMed         Abstract available

    Folia Med (Plovdiv)

  23. OEY O, Viswambaram P, Moe A, Swarbick N, et al
    Anterior pelvic exenteration and synchronous bilateral nephroureterectomy for BK polyoma virus induced urothelial carcinoma of the bladder: A case report.
    Folia Med (Plovdiv). 2022;64:521-526.
    PubMed         Abstract available

    Free Radic Biol Med

  24. LIU S, Shi J, Wang L, Huang Y, et al
    Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling.
    Free Radic Biol Med. 2022;189:42-57.
    PubMed         Abstract available

    Front Genet

  25. ZHANG X, Liang H, Tang Q, Chen H, et al
    Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer.
    Front Genet. 2022;13:801665.
    PubMed         Abstract available

  26. SUN X, Xin S, Li W, Zhang Y, et al
    Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer.
    Front Genet. 2022;13:928778.
    PubMed         Abstract available

    Front Immunol

  27. Erratum: Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Front Immunol. 2022;13:975797.
    PubMed         Abstract available

  28. LIU D, Xu S, Chang T, Ma S, et al
    Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Front Immunol. 2022;13:916800.
    PubMed         Abstract available

    Front Oncol

  29. WANG L, Shi J, Liu S, Huang Y, et al
    RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway.
    Front Oncol. 2022;12:915240.
    PubMed         Abstract available

    Hinyokika Kiyo

  30. YAMASHITA Y, Miura T, Kawamura S, Sumii K, et al
    [Treatment of Parastomal Hernia Following Robot-Assisted Radical Cystectomy and Cutaneous Ureterostomy : A Case Report].
    Hinyokika Kiyo. 2022;68:197-199.
    PubMed         Abstract available

    Int Braz J Urol

  31. MEDINA LG, Alsyouf M, Ghoreifi A, Sayegh AS, et al
    Distal ureter and bladder cuff excision using the "Keyhole Technique" during Robotic Radical Nephroureterectomy.
    Int Braz J Urol. 2022;48:876-877.
    PubMed         Abstract available

    Int J Surg

  32. LI Z, Zhou Z, Cui Y, Zhang Y, et al
    Systematic review and meta-analysis of randomized controlled trials of perioperative outcomes and prognosis of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer.
    Int J Surg. 2022;104:106777.
    PubMed         Abstract available

    Int J Urol

  33. MURAKAMI Y, Matsumoto K, Miyake M, Amano N, et al
    Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14976.
    PubMed         Abstract available

  34. TOCHIGI K, Nagayama J, Bando S, Ishiyama A, et al
    Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14974.
    PubMed         Abstract available

  35. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.15000.

  36. IDE H
    Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14988.

    J Biomol Tech

  37. BARAU C, Maille P, Sirab N, Ghaleh B, et al
    Automated DNA, RNA, and Protein Extraction from Urine for Biobanking.
    J Biomol Tech. 2022;33.
    PubMed         Abstract available

    J Environ Public Health

  38. CABALLERO JM, Perez-Marquez M, Gili JM, Pereira JC, et al
    Environmental Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain.
    J Environ Public Health. 2022;2022:1051046.
    PubMed         Abstract available

    J Exp Clin Cancer Res

  39. TAN Z, Jiang Y, Liang L, Wu J, et al
    Dysregulation and prometastatic function of glycosyltransferase C1GALT1 modulated by cHP1BP3/ miR-1-3p axis in bladder cancer.
    J Exp Clin Cancer Res. 2022;41:228.
    PubMed         Abstract available

    J Glob Antimicrob Resist

  40. XU H, Cao X, Zhang W, Li Q, et al
    Co-existence of two ciprofloxacin-resistant Salmonella enterica serovar Kentucky strains in the urine of a bladder cancer patient.
    J Glob Antimicrob Resist. 2022 Jul 13. pii: S2213-7165(22)00177.

    J Hematol Oncol

  41. ZHANG W, He X, Yin H, Cao W, et al
    Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.
    J Hematol Oncol. 2022;15:93.
    PubMed         Abstract available

    J Med Case Rep

  42. SINHA A, Patterson B
    Persistently elevated beta-human chorionic gonadotropin level after vacuum-assisted uterine aspiration: a case report.
    J Med Case Rep. 2022;16:279.
    PubMed         Abstract available

    J Transl Med

  43. HUANG Z, Yan Y, Wang T, Wang Z, et al
    Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
    J Transl Med. 2022;20:315.
    PubMed         Abstract available

    J Urol

  44. BREE KK, Hensley PJ, Lobo N, Brooks NA, et al
    All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors.
    J Urol. 2022;208:284-291.
    PubMed         Abstract available

  45. HAKIMI K, Carbonara U, Djaladat H, Mehrazin R, et al
    Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.
    J Urol. 2022;208:268-276.
    PubMed         Abstract available

    Minerva Surg

  46. LI Y, Xiao M, Xiao L
    Report of a case of paraganglioma of the urinary bladder: a discussion of the surgical approach.
    Minerva Surg. 2022;77:416-418.

    Minerva Urol Nephrol

  47. LAYMON M, Mosbah A, Hashem A, Elsawy AA, et al
    Predictors and survival benefit of achieving pentafecta in a contemporary series of open radical cystectomy.
    Minerva Urol Nephrol. 2022;74:428-436.
    PubMed         Abstract available

    Mol Imaging Biol

  48. HOANG TT, Mandleywala K, Viray T, Tan KV, et al
    EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.
    Mol Imaging Biol. 2022;24:511-518.
    PubMed         Abstract available

    Mol Ther Oncolytics

  49. MOKKAPATI S, Narayan VM, Manyam GC, Lim AH, et al
    Lentiviral interferon: A novel method for gene therapy in bladder cancer.
    Mol Ther Oncolytics. 2022;26:141-157.
    PubMed         Abstract available


  50. DUM D, Taherpour N, Menz A, Hoflmayer D, et al
    Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
    Pathobiology. 2022;89:245-258.
    PubMed         Abstract available


  51. ANDERSON JA, Matoso A, Murati Amador BI, Cheng L, et al
    Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study.
    Pathology. 2021;53:214-219.
    PubMed         Abstract available

    PLoS One

  52. JURI H, Higashiyama A, Yamamoto K, Narumi Y, et al
    Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS.
    PLoS One. 2022;17:e0271470.
    PubMed         Abstract available

    Sci Rep

  53. FURUYA H, Sasaki Y, Chen R, Peres R, et al
    PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity.
    Sci Rep. 2022;12:12186.
    PubMed         Abstract available

    Urol Oncol

  54. FU T, Lin Y, Lin L, Yang Y, et al
    Network architecture of non-coding RNAs provides insights into the pathogenesis of upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:383.
    PubMed         Abstract available

  55. BURGESS EF, Sanders JA, Livasy C, Symanowski J, et al
    Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
    Urol Oncol. 2022;40:383.
    PubMed         Abstract available

  56. CARVALHO FLF, Wang Y, Dall CP, Nayan M, et al
    Preoperative anemia is associated with increased radical cystectomy complications.
    Urol Oncol. 2022;40:382.
    PubMed         Abstract available

  57. YONG C, Mott SL, Steinberg RL, Packiam VT, et al
    A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience.
    Urol Oncol. 2022 Jul 10. pii: S1078-1439(22)00226.
    PubMed         Abstract available


  58. ISCAIFE A, Ribeiro Filho LA, Aparecido Pereira MW, Gallucci FP, et al
    Holmium Laser Resection of Large Bladder Tumors: Technique Description, Feasibility, and Histopathological Quality Analysis.
    Urology. 2022;165:373.
    PubMed         Abstract available

  59. ALSYOUF M, Daneshmand S
    Re: Detection Rate of CIS During TURBT Following Shift From PDD to NBI in a Single University Hospital.
    Urology. 2022;165:e47.

  60. RASMUSSEN M, Madsen MG, Therkildsen C
    Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review.
    Urology. 2022;165:44-53.
    PubMed         Abstract available

  61. KHONDAKAR NR, Lee P, McNeil BK
    Gross Hematuria in an Adolescent Secondary to a Rare Bladder Tumor: A Case Report and Review of Inflammatory Myofibroblastic Tumors of the Urinary Bladder.
    Urology. 2022;165:e39-e45.
    PubMed         Abstract available

  62. TSIVIAN M, Bole R, Packiam VT, Boorjian SA, et al
    The Association of Trainee Involvement in Radical Cystectomy With Perioperative and Oncologic Outcomes.
    Urology. 2022;165:128-133.
    PubMed         Abstract available

    World J Urol

  63. CANCRINI F, Michel F, Cussenot O, Alshehhi H, et al
    Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?
    World J Urol. 2022;40:1949-1959.
    PubMed         Abstract available

  64. SONG Y, Han J, Qin C, Du Y, et al
    Whether diagnostic ureteroscopic biopsy and ureteroscopy without biopsy have different impacts on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy?
    World J Urol. 2022;40:2135-2137.

  65. WISHAHI M, Otto T, Golka K
    Re: bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis-are they the same tumors?
    World J Urol. 2022;40:2139-2140.

  66. CONCONI D, Jemma A, Giambra M, Redaelli S, et al
    Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B.
    World J Urol. 2022 Jul 16. pii: 10.1007/s00345-022-04093.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.